Clinical trial · Interventional
Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology
Development of a Novel Method to Detect Prostate Cancer Circulating Tumor Cells (CTCs) Based on Epithelial-mesenchymal Transition Biology
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a minimal risk correlative clinical blood-drawing protocol. The objective of this lead in pilot component is to determine whether Circulating Tumor Cells (CTC's) can be captured using the novel mesenchymal-marker based Near Infrared-Emissive Polymersomes (NIR-EPs), the PSMA-based NIR-EP, and the epithelial EpCAM-based NIR-EP. If successful, the capture method will be evaluated further in the larger comparative study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Near infrared (NIR) emissive nanotechnology | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Metastatic prostate cancer
- description
- Near infrared (NIR) emissive nanotechnology
- interventionNames
- Device: Near infrared (NIR) emissive nanotechnology
Primary outcomes (1)
- measure
- Change in Non-detection rate of CTC's in men with CRPC
- timeFrame
- at baseline, month 3, and progression (up to 18 months)
- description
- Non-detection rate of CTC's in men with CRPC will be measured at baseline, month 3, and at progression
Secondary outcomes (10)
- measure
- Median number of CTC's detected by each capture method
- timeFrame
- baseline, month 3, and progression (up to 18 months)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed diagnosis of adenocarcinoma of the prostate * Clinical or radiographic evidence of metastatic disease * Evidence of disease progression on androgen deprivation therapy (ADT) as evidenced by either of the following in the past: 1. Two consecutive PSA levels greater than the PSA nadir achieved on ADT, separated by greater than one week 2. Radiographic evidence of disease progression as defined by new bone scan lesions or soft tissue/visceral metastases \>2 cm in diameter. 3. Clinical progression as determined by the treating physician. * Age greater than 18 years. * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * History of intercurrent or past medical or psychiatric illness that would make participation in a blood drawing protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s)
References
Publications (0)
Data not yet available